about
Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fateHemophilia A inhibitor treatment: the promise of engineered T-cell therapy.Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation.Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivoEngineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells
P50
description
researcher (ORCID 0000-0003-4918-2610)
@en
wetenschapper
@nl
name
David W Scott
@en
David W Scott
@nl
type
label
David W Scott
@en
David W Scott
@nl
prefLabel
David W Scott
@en
David W Scott
@nl
P31
P496
0000-0003-4918-2610